Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis.

The adult skeleton regenerates by temporary cellular structures that comprise teams of juxtaposed osteoclasts and osteoblasts and replace periodically old bone with new. A considerable body of evidence accumulated during the last decade has shown that the rate of genesis of these two highly specialized cell types, as well as the prevalence of their apoptosis, is essential for the maintenance of bone homeostasis; and that common metabolic bone disorders such as osteoporosis result largely from a derangement in the birth or death of these cells. The purpose of this article is 3-fold: 1) to review the role and the molecular mechanism of action of regulatory molecules, such as cytokines and hormones, in osteoclast and osteoblast birth and apoptosis; 2) to review the evidence for the contribution of changes in bone cell birth or death to the pathogenesis of the most common forms of osteoporosis; and 3) to highlight the implications of bone cell birth and death for a better understanding of the mechanism of action and efficacy of present and future pharmacotherapeutic agents for osteoporosis.

[1]  N Loveridge,et al.  Identification of apoptotic changes in osteocytes in normal and pathological human bone. , 1997, Bone.

[2]  E. Burger,et al.  Inhibiting and stimulating effects of TGF‐β1 on osteoclastic bone resorption in fetal mouse bone organ cultures , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Joie Davis,et al.  Mutations of CTSK Result in Pycnodysostosis via a Reduction in Cathepsin K Protein , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  K. Korach,et al.  Effect of testosterone and estradiol in a man with aromatase deficiency. , 1997, The New England journal of medicine.

[5]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[6]  S. Rudikoff,et al.  A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo1. , 1999, Endocrinology.

[7]  C. Christiansen,et al.  Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. , 2002, Bone.

[8]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[9]  E. Jimi,et al.  Regulation of Osteoclast Function , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  L. Klenerman,et al.  ANABOLIC EFFECT OF LOW DOSES OF A FRAGMENT OF HUMAN PARATHYROID HORMONE ON THE SKELETON IN POSTMENOPAUSAL OSTEOPOROSIS , 1976, The Lancet.

[11]  G. Stein,et al.  Osteocalcin gene promoter: Unlocking the secrets for regulation of osteoblast growth and differentiation , 1998, Journal of cellular biochemistry.

[12]  D. Goltzman,et al.  In vivo distribution of parathyroid hormone receptors in bone: evidence that a predominant osseous target cell is not the mature osteoblast. , 1988, Endocrinology.

[13]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[14]  W. Ambrosius,et al.  Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. , 1997, Bone.

[15]  A. Boskey,et al.  Matrix proteins and mineralization: an overview. , 1996, Connective tissue research.

[16]  P. Roberson,et al.  Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. , 1999, The Journal of clinical investigation.

[17]  L. Melton,et al.  Evidence for two distinct syndromes of involutional osteoporosis. , 1983, The American journal of medicine.

[18]  G. Wesolowski,et al.  Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Srivastava,et al.  Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. , 2001, Endocrinology.

[20]  Z. Wu,et al.  Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids , 1996, Molecular and cellular biology.

[21]  J. Glowacki,et al.  In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. , 1998, The Journal of clinical endocrinology and metabolism.

[22]  E. Opas,et al.  The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. , 1993, The Journal of clinical investigation.

[23]  A. Friedenstein,et al.  STROMAL CELLS RESPONSIBLE FOR TRANSFERRING THE MICROENVIRONMENT OF THE HEMOPOIETIC TISSUES: Cloning In Vitro and Retransplantation In Vivo , 1974, Transplantation.

[24]  H. Fleisch Bisphosphonates: Mechanisms of Action , 1998 .

[25]  G. David Roodman,et al.  Paget disease of bone , 2012, Radiopaedia.org.

[26]  C. Christiansen,et al.  Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. , 1999, Bone.

[27]  L. Banks,et al.  Effect of degenerative spinal and aortic calcification on bone density measurements in post‐menopausal women: links between osteoporosis and cardiovascular disease? , 1994, European journal of clinical investigation.

[28]  I. Semba,et al.  Higher osteoclastic demineralization and highly mineralized cement lines with osteocalcin deposition in a mandibular cortical bone of autosomal dominant osteopetrosis type II: ultrastructural and undecalcified histological investigations. , 2000, Bone.

[29]  S. Razzouk,et al.  Rac-GTPase, osteoclast cytoskeleton and bone resorption. , 1999, European journal of cell biology.

[30]  A. Boyde,et al.  Marrow stromal (Western-Bainton) cells: identification, morphometry, confocal imaging and changes in disease. , 1993, Bone.

[31]  T. Komori,et al.  Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). , 1998, Biochemical and biophysical research communications.

[32]  A. Parfitt,et al.  Osteoblast Programmed Cell Death (Apoptosis): Modulation by Growth Factors and Cytokines , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  G. Passeri,et al.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. , 1992, The Journal of clinical investigation.

[34]  S. Marks,et al.  The origin of osteoclasts: evidence, clinical implications and investigative challenges of an extra-skeletal source. , 1983, Journal of oral pathology.

[35]  R. Scandurra,et al.  The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. , 2002, Bone.

[36]  D. Goltzman,et al.  Discoveries, drugs and skeletal disorders , 2002, Nature Reviews Drug Discovery.

[37]  D. Bainton,et al.  Association of alkaline-phosphatase-positive reticulum cells in bone marrow with granulocytic precursors , 1979, The Journal of experimental medicine.

[38]  L. Quarles,et al.  Guanine nucleotide binding‐protein coupled signaling pathway regulation of osteoblast‐mediated bone formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  R. Eastell,et al.  Cancellous bone remodeling in type i (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  J. Loutit Stem Cells—Their Identification and Characterisation , 1983, British Journal of Cancer.

[41]  A. F. Stewart PTHrP(1-36) as a skeletal anabolic agent for the treatment of osteoporosis. , 1996, Bone.

[42]  B. Boyce,et al.  Apoptosis in bone physiology and disease. , 1997, Molecular pathology : MP.

[43]  V. Rosen,et al.  Opposing effects by glucocorticoid and bone morphogenetic protein‐2 in fetal rat bone cell cultures , 1997, Journal of cellular biochemistry.

[44]  D. Frank,et al.  Competition between noggin and bone morphogenetic protein 4 activities may regulate dorsalization during Xenopus development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Lakatos,et al.  Serum interleukin-6 and bone metabolism in patients with thyroid function disorders. , 1997, The Journal of clinical endocrinology and metabolism.

[46]  J. Hock Stemming bone loss by suppressing apoptosis. , 1999, The Journal of clinical investigation.

[47]  J. Wergedal,et al.  Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in the rat. , 1975, Endocrinology.

[48]  T. Sunyer,et al.  Estrogen’s bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells , 1999 .

[49]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[50]  P. Saftig,et al.  The Bone Lining Cell: Its Role in Cleaning Howship's Lacunae and Initiating Bone Formation , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  S. Brooks,et al.  Relationship between estrogen structure and conformational changes in estrogen receptor/DNA complexes , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[52]  J. Kragstrup,et al.  A reconstruction of the remodelling cycle in normal human cortical iliac bone. , 1991, Bone and mineral.

[53]  J. Heersche,et al.  Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. , 1982, Endocrinology.

[54]  V. Rosen,et al.  Differential Roles for Bone Morphogenetic Protein (BMP) Receptor Type IB and IA in Differentiation and Specification of Mesenchymal Precursor Cells to Osteoblast and Adipocyte Lineages , 1998, The Journal of cell biology.

[55]  A. Parfitt,et al.  Increased Adipogenesis and Myelopoiesis in the Bone Marrow of SAMP6, a Murine Model of Defective Osteoblastogenesis and Low Turnover Osteopenia , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[56]  G. Yancopoulos,et al.  Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. , 1996, The Journal of clinical investigation.

[57]  S. Kato,et al.  Rapid activation of MAP kinase by estrogen in the bone cell line. , 1997, Biochemical and biophysical research communications.

[58]  G. Mundy,et al.  Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.

[59]  J. Simpkins,et al.  Phenolic A ring requirement for the neuroprotective effects of steroids , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[60]  R. Baron,et al.  Dissociation between bone resorption and bone formation in osteopenic transgenic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[61]  G. Wesolowski,et al.  Phosphatidylinositol 3-kinase association with the osteoclast cytoskeleton, and its involvement in osteoclast attachment and spreading. , 1997, Experimental cell research.

[62]  S. C. Lin,et al.  Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. , 1998, Proceedings of the Association of American Physicians.

[63]  Yuqiong Liang,et al.  Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification , 1999, Nature Genetics.

[64]  J. Compston,et al.  Bone Remodeling and Structure in Postmenopausal Women Treated with Long-Term, High-Dose Estrogen Therapy , 1999, Osteoporosis International.

[65]  T. Chambers,et al.  Prostaglandin E2 cooperates with TRANCE in osteoclast induction from hemopoietic precursors: synergistic activation of differentiation, cell spreading, and fusion. , 1999, Endocrinology.

[66]  J. Adachi,et al.  Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. , 2000, Bone.

[67]  P. Schlesinger,et al.  Expression and Regulation of RAB3 Proteins in Osteoclasts and Their Precursors , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[68]  M. Oursler,et al.  Estrogen modulation of osteoclast lysosomal enzyme secretion , 1995, Journal of cellular biochemistry.

[69]  Y. Bi,et al.  Regulation of osteoclast activity. , 1999, Life sciences.

[70]  D. Lacey,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in , 2022 .

[71]  P. Roberson,et al.  Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. , 1999, The Journal of clinical investigation.

[72]  F. Melsen,et al.  A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. , 1990, Bone.

[73]  J. Simpkins,et al.  Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione , 1998, Neuroscience.

[74]  R. Turner,et al.  Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. , 1995, Endocrinology.

[75]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[76]  H. Haugen,et al.  Developmental abnormalities in mice transgenic for bovine oncostatin M , 1995, Molecular and cellular biology.

[77]  F. Melsen,et al.  Formation of osteoblast‐like cells from human mononuclear bone marrow cultures , 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[78]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[79]  S. Freytag,et al.  Ectopic expression of the CCAAT/enhancer-binding protein alpha promotes the adipogenic program in a variety of mouse fibroblastic cells. , 1994, Genes & development.

[80]  C. Watson,et al.  Estrogen Receptor-α Detected on the Plasma Membrane of Aldehyde-Fixed GH3/B6/F10 Rat Pituitary Tumor Cells by Enzyme-Linked Immunocytochemistry. , 1999, Endocrinology.

[81]  A. Boskey Biomineralization: Conflicts, challenges, and opportunities , 1998, Journal of cellular biochemistry.

[82]  P. Lehenkari,et al.  Removal of osteoclast bone resorption products by transcytosis. , 1997, Science.

[83]  Renny T. Franceschi,et al.  Role of the α2-Integrin in Osteoblast-specific Gene Expression and Activation of the Osf2 Transcription Factor* , 1998, The Journal of Biological Chemistry.

[84]  S. McKnight,et al.  Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins. , 1995, Genes & development.

[85]  G. Roodman Paget's disease and osteoclast biology. , 1996, Bone.

[86]  T. Martin,et al.  Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[87]  L. Bonewald,et al.  Role of active and latent transforming growth factor beta in bone formation. , 1994, Journal of cellular biochemistry.

[88]  C Marcelli,et al.  Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[89]  J Reeve,et al.  Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. , 1980, British medical journal.

[90]  D. Lacey,et al.  Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1. , 1999, Endocrinology.

[91]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[92]  Hen-Li Chen,et al.  Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. , 2002, Endocrinology.

[93]  R. Hynes,et al.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. , 2000, The Journal of clinical investigation.

[94]  A R Pettit,et al.  TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.

[95]  B. Riggs,et al.  Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[96]  S. Teitelbaum,et al.  Osteoclastic bone resorption by a polarized vacuolar proton pump. , 1989, Science.

[97]  B. Riggs,et al.  Avian osteoclasts as estrogen target cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Michael C. Ostrowski,et al.  The Microphthalmia Transcription Factor Regulates Expression of the Tartrate‐Resistant Acid Phosphatase Gene During Terminal Differentiation of Osteoclasts , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[99]  M. Jourdan,et al.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. , 1991, Blood.

[100]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[101]  B. Riggs,et al.  Unitary Model of Osteoporosis Revisited , 1998 .

[102]  J. Triffitt,et al.  Adipocytic cells cultured from marrow have osteogenic potential. , 1991, Journal of cell science.

[103]  S. Manolagas Cellular and molecular mechanisms of osteoporosis , 1998, Aging.

[104]  C. Christiansen,et al.  Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. , 1992, The Journal of clinical endocrinology and metabolism.

[105]  R. Pacifici Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis-The Second Decade. , 1998, Endocrinology.

[106]  M. Odeh,et al.  Role of cytokines in rheumatoid arthritis. , 1998, Drug news & perspectives.

[107]  P. Nijweide,et al.  Function of osteocytes in bone , 1994, Journal of cellular biochemistry.

[108]  Shi Wei,et al.  Tumor Necrosis Factor α Regulatesα vβ5 Integrin Expression by Osteoclast Precursors in Vitro and in Vivo1. , 2000, Endocrinology.

[109]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[110]  M. Tavassoli Fatty Involution of Marrow and the Role of Adipose Tissue in Hemopoiesis , 1989 .

[111]  Abstract , 1952 .

[112]  G. Yancopoulos,et al.  Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.

[113]  H. Kishimoto [Bisphosphonates: pharmacology and use in the treatment of osteoporosis]. , 2002, Nihon rinsho. Japanese journal of clinical medicine.

[114]  H. Takayanagi,et al.  Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. , 1999, Journal of Clinical Investigation.

[115]  M. Whyte Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. , 1994, Endocrine reviews.

[116]  J. Li,et al.  Bisphosphonate Treatment Suppresses Not Only Stochastic Remodeling but Also the Targeted Repair of Microdamage , 2001, Calcified Tissue International.

[117]  S. Manolagas The role of IL-6 type cytokines and their receptors in bone. , 1998, Annals of the New York Academy of Sciences.

[118]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[119]  W. Wiktor-Jedrzejczak,et al.  Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. , 1991, Experimental hematology.

[120]  R. Harland,et al.  The Spemann Organizer Signal noggin Binds and Inactivates Bone Morphogenetic Protein 4 , 1996, Cell.

[121]  J. Risteli,et al.  Estrogen Reduces the Depth of Resorption Pits by Disturbing the Organic Bone Matrix Degradation Activity of Mature Osteoclasts. , 2001, Endocrinology.

[122]  V. Han,et al.  Regional variation of insulin-like growth factor-I gene expression in mature rat bone and cartilage. , 1994, Bone.

[123]  V. Parikka,et al.  Downregulation of Small GTPase Rab7 Impairs Osteoclast Polarization and Bone Resorption* 210 , 2001, The Journal of Biological Chemistry.

[124]  O. Jaillon,et al.  The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. , 2000, Bone.

[125]  J. Wrana,et al.  The Xenopus Dorsalizing Factor noggin Ventralizes Drosophila Embryos by Preventing DPP from Activating Its Receptor , 1996, Cell.

[126]  W. O'Fallon,et al.  Relationship of Bone Turnover to Bone Density and Fractures , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[127]  T. Martin,et al.  Coupling of Bone Resorption and Formation during Bone Remodeling , 2001 .

[128]  楢崎 雅司 Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130 , 1994 .

[129]  S. Manolagas Bone marrow, cytokines, and bone remodeling , 1995 .

[130]  Jill Moss,et al.  Mesenchymal precursor cells in the blood of normal individuals , 2000, Arthritis Research & Therapy.

[131]  D. Fisher,et al.  Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[132]  R. Baron,et al.  The mouse osteopetrotic grey-lethal mutation induces a defect in osteoclast maturation/function. , 2001, Bone.

[133]  D. Lacey,et al.  The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.

[134]  R. Ziegler,et al.  Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. , 1995, The Journal of clinical endocrinology and metabolism.

[135]  N. Franchimont,et al.  Platelet-derived growth factor stimulates the synthesis of interleukin-6 in cells of the osteoblast lineage. , 1995, Endocrinology.

[136]  M. Degli-Esposti To die or not to die—the quest of the TRAIL receptors , 1999, Journal of leukocyte biology.

[137]  Sheila J. Jones,et al.  Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. , 1996, Development.

[138]  T. Serikawa,et al.  Identification of peak bone mass QTL in a spontaneously osteoporotic mouse strain , 1999, Mammalian Genome.

[139]  J. Caulfield,et al.  Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34). , 1995, Endocrinology.

[140]  R. Gordon,et al.  Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. , 2001, The American journal of pathology.

[141]  T. Pappas,et al.  Membrane estrogen receptors identified by multiple antibody labeling and impeded‐ligand binding , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[142]  R. Baron,et al.  Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border , 1985, The Journal of cell biology.

[143]  H. Frost In vivo osteocyte death. , 1960, The Journal of bone and joint surgery. American volume.

[144]  C. Christiansen,et al.  Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. , 1999, The Journal of clinical endocrinology and metabolism.

[145]  D L Lacey,et al.  RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[146]  J. Bollerslev Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects. , 1989, Endocrine reviews.

[147]  P. Lips,et al.  Bone Histomorphometric and Biochemical Marker Results of a 2‐Year Placebo‐Controlled Trial of Raloxifene in Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[148]  K. Mann,et al.  Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. , 1988, The Journal of clinical endocrinology and metabolism.

[149]  K. Ozono,et al.  Increased IL-6-production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. , 1996, The Journal of clinical investigation.

[150]  T. Latifi,et al.  Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5. , 1998, Biochemistry.

[151]  Michael A. Banks,et al.  Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. , 1995, The Journal of clinical investigation.

[152]  Sheila J. Jones,et al.  Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[153]  A. Parfitt Osteonal and hemi‐osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone , 1994, Journal of cellular biochemistry.

[154]  Carla Palumbo,et al.  Structure-function relationships in the osteocyte. , 1990 .

[155]  T. Steiniche,et al.  Changes in bone histomorphometry after long‐term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[156]  J. Gimble,et al.  Osteoblastic gene expression during adipogenesis in hematopoietic supporting murine bone marrow stromal cells , 1993, Journal of cellular physiology.

[157]  P. Roberson,et al.  Transcriptional Activation of the p21 WAF1,CIP1,SDI1 Gene by Interleukin-6 Type Cytokines , 1998, The Journal of Biological Chemistry.

[158]  T. Martin,et al.  Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors , 1995, The Journal of experimental medicine.

[159]  R. Landes,et al.  Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. , 2002, The Journal of clinical investigation.

[160]  A. M. Parfitt,et al.  Skeletal Heterogeneity and the Purposes of Bone Remodeling: Implications for the Understanding of Osteoporosis , 2001 .

[161]  C. Leu,et al.  The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. , 1998, Endocrinology.

[162]  D. Hewett‐Emmett,et al.  Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[163]  J. Delaissé,et al.  Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. , 1995, Journal of cell science.

[164]  T. Thornhill,et al.  Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. , 1998, The American journal of pathology.

[165]  S. Reddy,et al.  Control of osteoclast differentiation. , 1998, Critical reviews in eukaryotic gene expression.

[166]  R. Jilka,et al.  Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2 , 1999, Journal of cellular biochemistry.

[167]  S. Manolagas Editorial: Cell Number Versus Cell Vigor-What Really Matters to a Regenerating Skeleton? , 1999, Endocrinology.

[168]  J. Wit,et al.  The Role of Estrogen in the Control of Rat Osteocyte Apoptosis , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[169]  B. Frenkel,et al.  Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression. , 1997, Molecular endocrinology.

[170]  M. Lieberherr,et al.  Cell signaling and estrogens in female rat osteoblasts: A possible involvement of unconventional nonnuclear receptors , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[171]  L. Bonewald,et al.  Role of TGFβ in Bone Remodeling a , 1990 .

[172]  E. Orwoll,et al.  Quantitative Trait Loci Affecting Peak Bone Mineral Density in Mice , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[173]  R. L. Cain,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Catabolic Effects of Continuous Human PTH (1–38) in Vivo Is Associated with Sustained Stimulation of RANKL and Inhibition of Osteoprotegerin and Gene-Associated Bone Formation , 2022 .

[174]  T. Yoneda,et al.  Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[175]  A. Schulz,et al.  Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. , 2000, Human molecular genetics.

[176]  T. Martin,et al.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. , 1989, Endocrinology.

[177]  G. Ciliberto,et al.  Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.

[178]  C. O’Brien,et al.  STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.

[179]  M Horton,et al.  The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure. , 1995, Journal of cell science.

[180]  A. Kulkarni,et al.  Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. , 1993, The American journal of pathology.

[181]  Flemming Melsen,et al.  Cancellous Bone Remodeling Occurs in Specialized Compartments Lined by Cells Expressing Osteoblastic Markers , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[182]  E. Wagner,et al.  HIF-1 mediated upregulation of VEGF and VEGF-R in systemic sclerosis (SSc): Imbalance with angiostatic factors suggests VEGF as a novel option for the treatment of ischemia in patients with SSc , 2002, Annals of the rheumatic diseases.

[183]  E. Seeman,et al.  Osteoporosis in Men , 1999, Osteoporosis International.

[184]  K. Sewell CALCITONIN. , 1965, Reactions Weekly.

[185]  X. Liang,et al.  A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. , 2000, The Journal of clinical investigation.

[186]  J. Simpkins,et al.  Effects of 17β-estradiol on glucose transporter 1 expression and endothelial cell survival following focal ischemia in the rats , 1997, Experimental Brain Research.

[187]  A. Ray,et al.  On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion , 1990, Molecular and cellular biology.

[188]  S. C. Lin,et al.  Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow. , 1997, The Journal of clinical investigation.

[189]  D. Dempster,et al.  Effect of pH on bone resorption by rat osteoclasts in vitro. , 1986, Endocrinology.

[190]  E. Nishida,et al.  Differentiation and Transforming Growth Factor-β Receptor Down-regulation by Collagen-α2β1 Integrin Interaction Is Mediated by Focal Adhesion Kinase and Its Downstream Signals in Murine Osteoblastic Cells* , 1997, The Journal of Biological Chemistry.

[191]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[192]  W. Wiktor-Jedrzejczak,et al.  Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[193]  J. Milbrandt,et al.  Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1. , 1998, The Journal of clinical investigation.

[194]  G. Yancopoulos,et al.  The alphas, betas, and kinases of cytokine receptor complexes , 1993, Cell.

[195]  R. Jilka,et al.  Essential Requirement of BMPs‐2/4 for Both Osteoblast and Osteoclast Formation in Murine Bone Marrow Cultures from Adult Mice: Antagonism by Noggin , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[196]  S. Mohan,et al.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. , 1997, Endocrine reviews.

[197]  H. Broxmeyer,et al.  Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. , 1995, The Journal of clinical investigation.

[198]  A. Parfitt,et al.  Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. , 1996, The Journal of clinical investigation.

[199]  G. Rodan Osteopontin Overview , 1995, Annals of the New York Academy of Sciences.

[200]  G. Passeri,et al.  Interleukin-11: a new cytokine critical for osteoclast development. , 1994, The Journal of clinical investigation.

[201]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[202]  T. Chambers,et al.  The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. , 1983, The Journal of clinical endocrinology and metabolism.

[203]  E. Bonucci,et al.  Alkaline phosphatase positive precursors of adipocytes in the human bone marrow , 1988, British journal of haematology.

[204]  P. Delmas,et al.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[205]  F. Melsen,et al.  Reconstruction of the resorptive site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals. , 1984, Metabolic bone disease & related research.

[206]  R. Kimble,et al.  Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. , 1995, Endocrinology.

[207]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[208]  R. Pietras,et al.  Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells , 1977, Nature.

[209]  C. Christiansen,et al.  Mechanism of circadian variation in bone resorption. , 2002, Bone.

[210]  B. Riggs,et al.  Osteoclasts and transforming growth factor-beta: estrogen-mediated isoform-specific regulation of production. , 1996, Endocrinology.

[211]  A. Economides,et al.  Identification of mammalian noggin and its expression in the adult nervous system , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[212]  Roodman Gd Advances in bone biology : The osteoclast , 1996 .

[213]  N. Franchimont,et al.  Platelet-derived Growth Factor Induces Interleukin-6 Transcription in Osteoblasts through the Activator Protein-1 Complex and Activating Transcription Factor-2* , 1999, The Journal of Biological Chemistry.

[214]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[215]  C. Damsky,et al.  Fibronectin is a survival factor for differentiated osteoblasts. , 1998, Journal of cell science.

[216]  G. Greene,et al.  Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. , 1999, Molecular endocrinology.

[217]  J. Compston,et al.  Principles of Bone Biology , 1997 .

[218]  P. Couttet,et al.  Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures. , 2002, European cytokine network.

[219]  R. Lindsay,et al.  Anabolic actions of parathyroid hormone on bone. , 1993, Endocrine reviews.

[220]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[221]  C. Lowik,et al.  Colony stimulating factor‐1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid hormone and parathyroid hormone‐related protein , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[222]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6. , 1992, Science.

[223]  J. Rungby,et al.  Hormone Replacement Therapy Prevents Osteoclastic Hyperactivity: A Histomorphometric Study in Early Postmenopausal Women , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[224]  K. Korach,et al.  Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. , 1994, The New England journal of medicine.

[225]  T. Allen,et al.  Pericyte differentiation. , 1995, Clinical orthopaedics and related research.

[226]  L. Watson,et al.  Studies in Osteopetrosis , 1965, Archives of disease in childhood.

[227]  M C Farach-Carson,et al.  Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. , 1993, The Journal of biological chemistry.

[228]  M. Revilla,et al.  Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. , 1992, Bone and mineral.

[229]  F. Parhami,et al.  Atherogenic Diet and Minimally Oxidized Low Density Lipoprotein Inhibit Osteogenic and Promote Adipogenic Differentiation of Marrow Stromal Cells , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[230]  S. Mohan,et al.  Bone growth factors. , 1991, Clinical orthopaedics and related research.

[231]  M. Wiznerowicz,et al.  Interleukin‐6‐Type Cytokines and Their Receptors for Gene Therapy of Melanoma a , 1995, Annals of the New York Academy of Sciences.

[232]  J. Reeve,et al.  The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. , 1997, The Journal of clinical endocrinology and metabolism.

[233]  A. Friedenstein,et al.  Stromal stem cells: marrow-derived osteogenic precursors. , 1988, Ciba Foundation symposium.

[234]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[235]  D. Chang,et al.  Reduction in Transforming Growth Factor β Receptor I Expression and Transcription Factor CBFa1 on Bone Cells by Glucocorticoid* , 1998, The Journal of Biological Chemistry.

[236]  T. Martin,et al.  Hormonal Regulation of Osteoclast Function , 1998, Trends in Endocrinology & Metabolism.

[237]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6 , 1992 .

[238]  E. Canalis Inhibitory actions of glucocorticoids on skeletal growth. Is local insulin-like growth factor I to blame? , 1998, Endocrinology.

[239]  H. Frost,et al.  Tetracycline-based study of bone dynamics in pycnodysostosis. , 1971, Clinical orthopaedics and related research.

[240]  A. Schulz,et al.  Loss of the ClC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man , 2001, Cell.

[241]  A. Parfitt The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. , 1982, Metabolic bone disease & related research.

[242]  B. Riggs,et al.  Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. , 1996, The Journal of clinical endocrinology and metabolism.

[243]  R. Weinstein,et al.  New Developments in the Pathogenesis and Treatment of Steroid‐Induced Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[244]  J. Steinfort,et al.  Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[245]  M. Karsdal,et al.  Transforming Growth Factor-β-induced Osteoblast Elongation Regulates Osteoclastic Bone Resorption through a p38 Mitogen-activated Protein Kinase- and Matrix Metalloproteinase-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[246]  R. Turner,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society The Effects of Programmed Administration of Human Parathyroid Hormone Fragment (1–34) on Bone Histomorphometry and Serum Chemistry in Rats* , 2022 .

[247]  H. Weinstein,et al.  Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis. , 1999, The Journal of clinical investigation.

[248]  K. Becker,et al.  Principles and Practice of Endocrinology and Metabolism , 1990 .

[249]  B. Epker,et al.  Suggested Sequential Mode of Control of Changes in Cell Behaviour in Adult Bone Remodelling , 1965, Nature.

[250]  F. Ross,et al.  Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF-κB Ligand (RANKL)-induced JNK Activation* , 2001, The Journal of Biological Chemistry.

[251]  A. Parfitt,et al.  Theoretical perspective: A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates , 1996 .

[252]  E. Eriksen,et al.  Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. , 1986, Endocrine reviews.

[253]  J Dequeker,et al.  Biochemistry of bone. , 1988, Bailliere's clinical rheumatology.

[254]  R. Rizzoli,et al.  TRANSGENIC MICE EXPRESSING SOLUBLE TUMOR NECROSIS FACTOR-RECEPTOR ARE PROTECTED AGAINST BONE LOSS CAUSED BY ESTROGEN DEFICIENCY , 1997 .

[255]  W. Grzesik,et al.  Bone matrix RGD glycoproteins: Immunolocalization and interaction with human primary osteoblastic bone cells in vitro , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[256]  L. Melton,et al.  Involutional osteoporosis. , 1986, The New England journal of medicine.

[257]  J. Lewis,et al.  Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. , 1999, The Journal of clinical investigation.

[258]  C. Rosen,et al.  Growth Hormone, Insulin-like Growth Factors , 2001 .

[259]  C. Ware,et al.  Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. , 1995, Development.

[260]  A. Parfitt,et al.  Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. , 1998, The Journal of clinical investigation.

[261]  P. Schiller,et al.  Age‐Related Osteogenic Potential of Mesenchymal Stromal Stem Cells from Human Vertebral Bone Marrow , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[262]  E. Canalis Editorial: Inhibitory Actions of Glucocorticoids on Skeletal Growth. Is Local Insulin-Like Growth Factor I to Blame? , 1998, Endocrinology.

[263]  R. Baron,et al.  Murine bone marrow stromally derived BMS2 adipocytes support differentiation and function of osteoclast-like cells in vitro. , 1998, Endocrinology.

[264]  W. Murphy,et al.  Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. , 1996, The American journal of medicine.

[265]  G M Besser,et al.  Serum cytokines in thyrotoxicosis. , 1999, The Journal of clinical endocrinology and metabolism.

[266]  B. Gelb,et al.  Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency , 1996, Science.

[267]  T. Toth,et al.  Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. , 1998, JAMA.

[268]  T. Chambers,et al.  Calcitonin alters behaviour of isolated osteoclasts , 1982, The Journal of pathology.

[269]  T. Martin,et al.  Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. , 2002, The American journal of pathology.

[270]  B. Katzenellenbogen,et al.  Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[271]  J. Compston,et al.  Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis. , 1988, Gut.

[272]  M. Schena,et al.  Vinculin, talin, and integrins are localized at specific adhesion sites of malignant B lymphocytes , 1988 .

[273]  F. Reinholt,et al.  Chondroclasts and Osteoclasts in Bones of Young Rats: Comparison of Ultrastructural and Functional Features , 1998, Calcified Tissue International.

[274]  Silvia Bernardini,et al.  Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation , 2000, The Journal of cell biology.

[275]  S. Manolagas The Role of IL‐6 Type Cytokines and Their Receptors in Bonea a , 1998 .

[276]  B. McEwen,et al.  Estrogen actions in the central nervous system. , 1999, Endocrine reviews.

[277]  P. Roberson,et al.  Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. , 1998, The Journal of clinical investigation.

[278]  R. Jilka,et al.  Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. , 1998, Bone.

[279]  M. Nuttall,et al.  Human Trabecular Bone Cells Are Able to Express Both Osteoblastic and Adipocytic Phenotype: Implications for Osteopenic Disorders , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[280]  S. Enerbäck,et al.  The CCAAT/enhancer binding protein and its role in adipocyte differentiation: evidence for direct involvement in terminal adipocyte development. , 1991, The EMBO journal.

[281]  L. Bonewald,et al.  Latent Forms of Transforming Growth Factor-β (TGFβ) Derived from Bone Cultures: Identification of a Naturally Occurring 100-kDa Complex with Similarity to Recombinant Latent TGFβ , 1991 .

[282]  R. Karas,et al.  Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. , 1999, The Journal of clinical investigation.

[283]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[284]  A. Hall,et al.  G Proteins and Small GTPases: Distant Relatives Keep in Touch , 1998, Science.

[285]  G. Marotti The structure of bone tissues and the cellular control of their deposition. , 1996, Italian journal of anatomy and embryology = Archivio italiano di anatomia ed embriologia.

[286]  H. Shibuya,et al.  A BMP-inducible gene, dlx5, regulates osteoblast differentiation and mesoderm induction. , 1999, Developmental biology.

[287]  J. Gimble,et al.  The function of adipocytes in the bone marrow stroma: an update. , 1996, Bone.

[288]  N. Udagawa,et al.  Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[289]  I. Reid,et al.  Glucocorticoid effects on bone. , 1998, The Journal of clinical endocrinology and metabolism.

[290]  H. Steller Mechanisms and genes of cellular suicide , 1995, Science.

[291]  D. Rao,et al.  Effects of Ethnicity and Age or Menopause on Osteoblast Function, Bone Mineralization, and Osteoid Accumulation in Iliac Bone , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[292]  P. Schlesinger,et al.  Passive chloride permeability charge coupled to H(+)-ATPase of avian osteoclast ruffled membrane. , 1991, The American journal of physiology.

[293]  G D Roodman,et al.  Cell biology of the osteoclast. , 1999, Experimental Hematology.

[294]  A. Galanos,et al.  A Randomized Trial of Nasal Spray Salmon Calcitonin in Men With Idiopathic Osteoporosis: Effects on Bone Mineral Density and Bone Markers , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[295]  M A Horton,et al.  A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. , 1997, The Journal of clinical investigation.

[296]  M. Horton,et al.  Trafficking of matrix collagens through bone-resorbing osteoclasts. , 1997, Science.

[297]  G. Roodman,et al.  Advances in bone biology: the osteoclast. , 1996, Endocrine reviews.

[298]  L. Mosekilde,et al.  Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. , 1993, Bone.

[299]  B. Spiegelman,et al.  Adipogenesis and Obesity: Rounding Out the Big Picture , 1996, Cell.

[300]  N. Takahashi,et al.  Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. , 1996, Endocrinology.

[301]  Thiennu H. Vu,et al.  Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones , 2000, The Journal of cell biology.

[302]  S. Nesbitt,et al.  β1 integrins and osteoclast function: Involvement in collagen recognition and bone resorption , 1996 .

[303]  A. Bilancio,et al.  Non‐transcriptional action of oestradiol and progestin triggers DNA synthesis , 1999, The EMBO journal.

[304]  D. Mcnulty,et al.  Proteolytic Activity of Human Osteoclast Cathepsin K , 1996, The Journal of Biological Chemistry.

[305]  G. Yancopoulos,et al.  Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. , 1994, The Journal of biological chemistry.

[306]  J. Risteli,et al.  Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. , 2000, Bone.

[307]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[308]  S. Shany,et al.  Interaction Between Estrogen and Vitamin D–Endocrine System: A Potential Addition to the Unitary Model of Osteoporosis , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[309]  B. Spiegelman,et al.  Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[310]  G. Marotti,et al.  A quantitative evaluation of osteoblast-osteocyte relationships on growing endosteal surface of rabbit tibiae. , 1992, Bone.

[311]  H. Genant,et al.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. , 1998, The Journal of clinical investigation.

[312]  J. Bilezikian,et al.  Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. , 1998, The New England journal of medicine.

[313]  Y. Koishihara,et al.  Endogenous bone‐resorbing factors in estrogen deficiency: Cooperative effects of IL‐1 and IL‐6 , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[314]  P. Goldhaber,et al.  H+ stimulation of cell-mediated bone resorption in tissue culture. , 1987, The American journal of physiology.

[315]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[316]  W. O'Fallon,et al.  Bone Density and Fracture Risk in Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[317]  R. Baron,et al.  Cellular kinetics of the bone remodeling sequence in the rat , 1982, The Anatomical record.

[318]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[319]  L. Lajtha Stem cell concepts. , 1979, Nouvelle revue francaise d'hematologie.

[320]  O. Verborgt,et al.  Loss of Osteocyte Integrity in Association with Microdamage and Bone Remodeling After Fatigue In Vivo , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[321]  M Dioszegi,et al.  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). , 2001, Human molecular genetics.

[322]  G D Roodman,et al.  Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. , 1992, The Journal of clinical investigation.

[323]  P. Roberson,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Activation of the Janus Kinase/STAT (Signal Transducer and Activator of Transcription) Signal Transduction Pathway by Interleukin-6-Type Cytokines Promotes , 2022 .

[324]  M. Hafner,et al.  Effects of estradiol-17 beta analogues on activation of estrogen response element regulated chloramphenicol acetyltransferase expression. , 1993, Biochemistry.

[325]  Gabriele Bergers,et al.  MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes , 1998, Cell.

[326]  T. Bouwmeester,et al.  Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer , 1996, Nature.

[327]  K. Satomura,et al.  Circulating Skeletal Stem Cells , 2001, The Journal of cell biology.

[328]  N. Athanasou,et al.  Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. , 2000, Bone.

[329]  J. Chow,et al.  Nitric oxide synthase expression in bone cells. , 1998, Bone.

[330]  Nils Brünner,et al.  Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[331]  B. Gelb,et al.  Determination of Bone Markers in Pycnodysostosis: Effects of Cathepsin K Deficiency on Bone Matrix Degradation , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[332]  J. Parsons,et al.  Identification and characterization of a novel cytoskeleton-associated pp60src substrate , 1991, Molecular and cellular biology.

[333]  F. Ross,et al.  Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. , 1999, The Journal of clinical investigation.

[334]  R. Kitazawa,et al.  Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. , 1994, The Journal of clinical investigation.

[335]  P. W. Johnston,et al.  Nitric oxide: A cytokine‐induced regulator of bone resorption , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[336]  M. Lazar,et al.  Peroxisome Proliferator Activated Receptor γ, CCAAT/ Enhancer-binding Protein α, and Cell Cycle Status Regulate the Commitment to Adipocyte Differentiation* , 1997, The Journal of Biological Chemistry.

[337]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[338]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[339]  S. Rodan,et al.  Sphingosine kinase mediates cyclic AMP suppression of apoptosis in rat periosteal cells. , 1998, Molecular pharmacology.

[340]  M. Oursler,et al.  Estrogen modulation of avian osteoclast lysosomal gene expression. , 1993, Endocrinology.

[341]  H. Okamura,et al.  Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. , 1997 .

[342]  Subburaman Mohan,et al.  Growth factors to stimulate bone formation , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[343]  E. Canalis,et al.  Skeletal growth factors. , 2000, Critical reviews in eukaryotic gene expression.

[344]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[345]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[346]  Harold M. Frost,et al.  Bone remodeling and its relationship to metabolic bone diseases , 1973 .

[347]  E. Salmon,et al.  Positive feedback interactions between microtubule and actin dynamics during cell motility. , 1999, Current opinion in cell biology.

[348]  T. Martin,et al.  Receptors of Calciotropic Hormones , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[349]  G. Rodan,et al.  High Fatty Acid Content in Rabbit Serum Is Responsible for the Differentiation of Osteoblasts Into Adipocyte‐like Cells , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[350]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[351]  A. Parfitt Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. , 2002, Bone.

[352]  Lynn Wei,et al.  Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. , 1997, The Journal of clinical investigation.

[353]  P. Garnero,et al.  Treatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene , 1999, Osteoporosis International.

[354]  P. Astrup,et al.  The acid-base metabolism. A new approach. , 1960, Lancet.

[355]  S. Majumdar,et al.  Insulin‐Like Growth Factor I Is Required for the Anabolic Actions of Parathyroid Hormone on Mouse Bone , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[356]  S. Shibata,et al.  An ultrastructural study of osteoclasts and chondroclasts in poorly calcified mandible induced by high doses of strontium diet to fetal mice. , 2001, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[357]  B. Riggs,et al.  Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[358]  F. Melsen,et al.  Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. , 1989, Bone.

[359]  J. Tobias,et al.  Early effects of hormone replacement therapy on bone. , 1999, Bone.

[360]  A. Villanueva,et al.  Relations between histologic indices of bone formation: Implications for the pathogenesis of spinal osteoporosis , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[361]  I. Kola,et al.  Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[362]  K. Hultenby,et al.  Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport. , 2002, Experimental cell research.

[363]  S. Manolagas Cell number versus cell vigor--what really matters to a regenerating skeleton? , 1999, Endocrinology.

[364]  G. Gundersen,et al.  Rho Guanosine Triphosphatase Mediates the Selective Stabilization of Microtubules Induced by Lysophosphatidic Acid , 1998, The Journal of cell biology.

[365]  J. Pike,et al.  Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[366]  P. Schlesinger,et al.  Substrate Recognition by Osteoclast Precursors Induces C-src/Microtubule Association , 1997, The Journal of cell biology.

[367]  T. Yoneda,et al.  Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[368]  H. Gundersen,et al.  Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. , 1984, Metabolic bone disease & related research.

[369]  T. Miyata,et al.  Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. , 1997, Journal of the American Society of Nephrology : JASN.

[370]  H. Mankin,et al.  Nontraumatic necrosis of bone (osteonecrosis). , 1992, The New England journal of medicine.

[371]  A. Parfitt,et al.  The effects of androgen deficiency on murine bone remodeling and bone mineral density are mediated via cells of the osteoblastic lineage. , 1997, Endocrinology.

[372]  L Berga,et al.  Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. , 1989, Experimental hematology.

[373]  D B Burr,et al.  Targeted and nontargeted remodeling. , 2002, Bone.

[374]  D J Baylink,et al.  Glucocorticoid-induced osteoporosis. , 1983, The New England journal of medicine.

[375]  S. Manolagas,et al.  Osteopontin expression by osteoclast and osteoblast progenitors in the murine bone marrow: demonstration of its requirement for osteoclastogenesis and its increase after ovariectomy. , 1997, Endocrinology.

[376]  A. Parfitt The mechanism of coupling: a role for the vasculature. , 2000, Bone.

[377]  J. Darnell STATs and gene regulation. , 1997, Science.

[378]  Allan Bradley,et al.  Increased bone formation in osteocalcin-deficient mice , 1996, Nature.

[379]  B. Epker,et al.  RESORPTION PRECEDES FORMATIVE ACTIVITY. , 1964, Surgical forum.

[380]  Napoleone Ferrara,et al.  VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation , 1999, Nature Medicine.

[381]  S. Houssami,et al.  Calcitonin receptor isoforms in mouse and rat osteoclasts , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[382]  K. Hruska,et al.  Rho-A Is Critical for Osteoclast Podosome Organization, Motility, and Bone Resorption* , 2000, The Journal of Biological Chemistry.

[383]  G. Howard,et al.  Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[384]  C. Rosen,et al.  Chapter 78 – Growth Hormone, Insulin-like Growth Factors: Potential Applications and Limitations in the Management of Osteoporosis , 2001 .

[385]  H. Varmus,et al.  Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. , 1997, Genes & development.

[386]  S. Mohan,et al.  The insulin-like growth factor system and the coupling of formation to resorption. , 1995, Bone.

[387]  Y. Sasai,et al.  Dorsoventral Patterning in Xenopus: Inhibition of Ventral Signals by Direct Binding of Chordin to BMP-4 , 1996, Cell.